Home Health Almirall and Inserm Transfert to collaborate on vitiligo treatments

Almirall and Inserm Transfert to collaborate on vitiligo treatments

Almirall and Inserm Transfert to collaborate on vitiligo treatments

Almirall and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), have announced a licensing agreement and research collaboration to advance treatment options for vitiligo. The partnership will focus on identifying and developing a novel class of medicines that modulate the Wnt pathway, a key target involved in skin repigmentation.

The partnership with Inserm Transfert is part of SHINE, an initiative launched by Almirall that aims to boost innovation in dermatology by promoting collaborations with centres of excellence such as those recently announced with the University of Dundee and the University of Michigan. This project also allows for a deeper understanding of dermatological diseases, access to new technologies and the discovery of innovative therapeutic approaches.

Through this partnership, the knowledge of Prof. Thierry Passeron’s team at the Mediterranean Centre for Molecular Medicine, who has been at the forefront of research in vitiligo, will be combined with Almirall’s expertise in drug discovery to identify and develop new topical compounds for the treatment of the condition. Almirall has also been granted global rights to Inserm’s background patents on the use of Wnt agonists in the treatment of vitiligo.

Karl Ziegelbauer, PhD, Chief Scientific Officer at Almirall said: “Vitiligo can have a huge impact on patients’ quality of life. We are pleased to announce this new collaboration with a centre of excellence such as Inserm to develop innovative treatments for this skin condition. This milestone once again demonstrates Almirall’s commitment to improving the lives of patients in an underserved disease where there are still significant unmet need.

Volker Koscielny, MD, Chief Medical Officer at Almirall said:The collaboration with Prof. Passeron’s group is a prime example of Almirall’s desire to collaborate with academic centres of excellence to advance research into areas of significant unmet need. Building on the expertise of Almirall’s external Innovation & Licensing team, we are perfectly positioned to tap into an increasingly innovative and collaborative environment in Europe, as demonstrated by Inserm Transfert in France.”


Previous articleRevolut’s embedded finance partner Modulr bags $108m in new funding
Next articleNI scientists urged to end medical tests on dogs as charity pushes for better treatment for humans